福巴替尼的购买渠道有哪些？

Forbatinib is a targeted therapy for patients with FGFR gene-mutated cholangiocarcinoma. As a second-generation FGFR inhibitor, it provides a new treatment option for patients who are resistant to first-line treatment. At present, the drug has not yet been officially launched in mainland China, but patients can still obtain it through various channels. This article will introduce in detail the purchasing channels, global listing status and price information of forbatinib to help patients better understand this important anti-cancer drug.

What are the purchasing channels for fobatinib

For patients in urgent need of treatment, the drug can currently be obtained through the following main channels, each of which has its own characteristics and precautions.

Cross-border medical service institutions

Professional cross-border medical service institutions are one of the most reliable purchasing channels. These institutions usually cooperate with overseas regular pharmacies or hospitals and can provide guarantee of authenticity. They will assist patients to complete the full process of prescription review, drug procurement, customs declaration, etc., and provide formal drug traceability certificates.

Purchasing drugs overseas

Patients can purchase drugs from Laos, India and other countries. The price of generic drugs produced by Lucius in Laos is relatively low, about US$480 (4mg*35 tablets/box).

Participate in clinical trials

Some domestic hospitals may be conducting clinical trials related to forbatinib. Eligible patients can apply to participate through their attending physician and not only receive free drug treatment, but also receive professional medical monitoring. This is currently the most formal way to obtain it in the country.

When choosing purchase channels, patients should give priority to formality and safety to avoid drug quality issues that may affect treatment effects.

The marketing status of fobatinib

The global marketing process of fobatinib reflects the different paces of new drug approval in various countries. Understanding this information can help patients plan how to obtain the drug.

International Approval Status

Forbatinib was developed by Japan's Tahoe Pharmaceuticals. It received accelerated approval from the US FDA in October 2022, was approved in Japan in June 2023, and was approved by the European Union in July of the same year. These approvals are based on its significant clinical efficacy data and provide new treatment options for patients with cholangiocarcinoma.

China marketing progress

As of now, forbatinib has not yet been approved by the China National Medical Products Administration. According to the general process of new drug approval, it is expected to take several years before it can be launched in the country. Patients can follow the official website of the Food and Drug Administration or consult their attending doctor for the latest developments.

Production status of generic drugs

Pharmaceutical companies such as Lucius Laos have begun to produce generic drugs of forbatinib. These products are similar in ingredients and efficacy to the original drug, and the price is more advantageous. However, it should be noted that there are differences in the approval standards for generic drugs in different countries.

Understanding the global marketing status of forbatinib can help patients better plan their treatment and drug purchase plans.

The price of forbatinib

As a new targeted drug, the price of forbatinib is one of the focuses of patients' attention, and the prices of drugs from different sources vary greatly.

Original drug price

The original drug LYTGOBI produced by Japan's Tahoe Pharmaceuticals is relatively expensive and is a heavy burden for most patients, especially when long-term treatment is required.

Price of generic drugs

The price of generic drugs produced by Lucius in Laos is about US$480 (4mg*35 tablets/box). Based on the recommended dose of 20mg/day, the monthly treatment cost is about US$2,000.

In addition to the cost of the drug itself, other additional expenses need to be considered when purchasing through cross-border channels. Patients should understand the full cost structure in advance.